8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Mar 30, 2026·SEC
Agilon Health, Inc.(AGL)Earnings, Financials & Key Ratios
AGL•NYSE
$27.85
$464M mkt cap·Price updated May 6, 2026
Aboutagilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.Show more
- Revenue$5.93B-2.1%
- EBITDA-$392M-46.6%
- Net Income-$405M-55.8%
- EPS (Diluted)-24.50-55.6%
- Gross Margin-3.18%-4079.1%
- EBITDA Margin-6.62%-49.8%
- Operating Margin-7.1%-47.2%
- Net Margin-6.83%-59.2%
- ROE-135.64%-195.1%
- ROIC-203.16%-326.6%
- Debt/Equity0.29+211.2%
- Interest Coverage-59.85-52.4%
AGL Key Insights
Agilon Health, Inc. (AGL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓Strong 5Y sales CAGR of 37.2%
- ✓Efficient asset utilization: 4.7x turnover
✗Weaknesses
- ✗Profits declining 46.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AGL Price & Volume
Agilon Health, Inc. (AGL) stock price & volume — 10-year historical chart
Loading chart...
AGL Growth Metrics
Agilon Health, Inc. (AGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years37.24%
3 Years35.43%
TTM-2.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-54.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-53.9%
Return on Capital
10 Years-45.67%
5 Years-47.52%
3 Years-58.65%
Last Year-108.42%
AGL Recent Earnings
Agilon Health, Inc. (AGL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 25, 2026EPS
$11.50
Est $6.75
-70.4%
Revenue
$1.6B
Est $1.5B
+6.8%
Q4 2025
Nov 4, 2025EPS
$0.27
Est $0.18
-50.0%
Revenue
$1.4B
Est $1.4B
+1.0%
Q3 2025
Aug 4, 2025EPS
$0.25
Est $0.11
-127.3%
Revenue
$1.4B
Est $1.5B
-5.2%
Q2 2025
May 6, 2025EPS
$0.03
Est $0.01
+393.3%
Revenue
$1.5B
Est $1.5B
+1.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $11.50vs $6.75-70.4% | $1.6Bvs $1.5B+6.8% |
| Q4 2025 | Nov 4, 2025 | $0.27vs $0.18-50.0% | $1.4Bvs $1.4B+1.0% |
| Q3 2025 | Aug 4, 2025 | $0.25vs $0.11-127.3% | $1.4Bvs $1.5B-5.2% |
| Q2 2025 | May 6, 2025 | $0.03vs $0.01+393.3% | $1.5Bvs $1.5B+1.9% |
Based on last 12 quarters of dataView full earnings history →
AGL Peer Comparison
Agilon Health, Inc. (AGL) competitors in Physician platforms and value-based care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CNC | 27.31B | 55.32 | -4.06 | 19.44% | -3.25% | -28.6% | 0.94 | |
 HUM | 29.57B | 246.33 | 25.03 | 10.06% | 0.82% | 6.17% | 0.73 | |
 CVS | 111.32B | 86.86 | 62.49 | 7.85% | 0.72% | 3.86% | 1.24 | |
 ELV | 81.37B | 374.71 | 14.92 | 12.62% | 2.62% | 11.92% | 0.75 | |
 MOH | 10.28B | 197.44 | 22.13 | 11.75% | 0.42% | 4.44% | 0.97 | |
 OSCR | 5.14B | 19.84 | -11.74 | 27.5% | -0.3% | -3.26% | 0.44 | |
 CLOV | 1.37B | 2.68 | -15.76 | 40.34% | -2.58% | -17.08% | ||
 ALHC | 3.71B | 18.14 | -4902.70 | 46.06% | 0.47% | 11.5% | 1.89 |
Compare AGL vs Peers
Agilon Health, Inc. (AGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AGL Income Statement
Agilon Health, Inc. (AGL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 794.41M | 1.22B | 1.52B | 2.39B | 4.32B | 6.06B | 5.93B | 5.82B |
| Revenue Growth % | - | 53.36% | 24.88% | 56.97% | 80.74% | 40.41% | -2.11% | -2.82% |
| Cost of Goods Sold | 765.9M | 1.12B | 1.46B | 2.28B | 4.25B | 6.06B | 6.12B | 4.62B |
| COGS % of Revenue | 96.41% | 92.27% | 95.68% | 95.34% | 98.39% | 99.92% | 103.18% | - |
| Gross Profit | 28.51M▲ 0% | 94.15M▲ 230.2% | 65.74M▼ 30.2% | 111.36M▲ 69.4% | 69.67M▼ 37.4% | 4.84M▼ 93.1% | -188.61M▼ 3996.2% | -225.14M▲ 0% |
| Gross Margin % | 3.59% | 7.73% | 4.32% | 4.66% | 1.61% | 0.08% | -3.18% | -3.87% |
| Gross Profit Growth % | - | 230.22% | -30.17% | 69.38% | -37.44% | -93.05% | -3996.2% | - |
| Operating Expenses | 135.09M | 150.82M | 437.99M | 216.74M | 301.8M | 296.97M | 232.46M | 228.06M |
| OpEx % of Revenue | 17% | 12.38% | 28.79% | 9.08% | 6.99% | 4.9% | 3.92% | - |
| Selling, General & Admin | 122.83M | 137.29M | 427.5M | 207.79M | 285.76M | 268.91M | 238.54M | 222.72M |
| SG&A % of Revenue | 15.46% | 11.27% | 28.1% | 8.7% | 6.62% | 4.44% | 4.02% | - |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 12.25M | 13.53M | 10.48M | 8.95M | 16.04M | 28.06M | -6.08M | 0 |
| Operating Income | -106.57M▲ 0% | -56.67M▲ 46.8% | -372.24M▼ 556.8% | -105.38M▲ 71.7% | -232.13M▼ 120.3% | -292.13M▼ 25.8% | -421.08M▼ 44.1% | -394.97M▲ 0% |
| Operating Margin % | -13.42% | -4.65% | -24.47% | -4.41% | -5.38% | -4.82% | -7.1% | -6.79% |
| Operating Income Growth % | - | 46.82% | -556.82% | 71.69% | -120.29% | -25.85% | -44.14% | - |
| EBITDA | -65.16M | -42.57M | -357.57M | -91.61M | -211.97M | -267.67M | -392.48M | -366.46M |
| EBITDA Margin % | -8.2% | -3.49% | -23.5% | -3.84% | -4.91% | -4.42% | -6.62% | -6.3% |
| EBITDA Growth % | - | 34.66% | -739.88% | 74.38% | -131.4% | -26.27% | -46.63% | -30.15% |
| D&A (Non-Cash Add-back) | 41.41M | 14.1M | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M | 28.5M |
| EBIT | -105.62M | -54.21M | -376.83M | -86.19M | -187.8M | -242.65M | -397.45M | -397.28M |
| Net Interest Income | -9.07M | -8.13M | -6.15M | -4.48M | -6.66M | -6.18M | -6.64M | -5.13M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.07M | 8.13M | 6.15M | 4.48M | 6.66M | 6.18M | 6.64M | 3.31M |
| Other Income/Expense | -8.11M | -5.67M | -10.73M | 14.71M | 37.67M | 43.3M | 16.98M | 22.51M |
| Pretax Income | -114.69M▲ 0% | -62.34M▲ 45.6% | -382.98M▼ 514.3% | -90.67M▲ 76.3% | -194.46M▼ 114.5% | -248.83M▼ 28.0% | -404.1M▼ 62.4% | -372.46M▲ 0% |
| Pretax Margin % | -14.44% | -5.12% | -25.17% | -3.8% | -4.51% | -4.11% | -6.81% | -6.4% |
| Income Tax | -232K | 865K | 886K | 1.64M | 791K | 1.45M | 1.25M | 1.03M |
| Effective Tax Rate % | 0.2% | -1.39% | -0.23% | -1.81% | -0.41% | -0.58% | -0.31% | -0.28% |
| Net Income | -282.59M▲ 0% | -60.05M▲ 78.7% | -406.49M▼ 576.9% | -106.55M▲ 73.8% | -262.6M▼ 146.4% | -260.15M▲ 0.9% | -405.35M▼ 55.8% | -373.49M▲ 0% |
| Net Margin % | -35.57% | -4.93% | -26.72% | -4.46% | -6.08% | -4.29% | -6.83% | -6.42% |
| Net Income Growth % | - | 78.75% | -576.89% | 73.79% | -146.45% | 0.93% | -55.81% | -54.35% |
| Net Income (Continuing) | -114.45M | -63.21M | -383.86M | -92.31M | -195.25M | -250.28M | -405.35M | -373.49M |
| Discontinued Operations | 0 | 3.16M | -22.93M | -14.55M | -67.55M | -9.82M | 0 | 0 |
| Minority Interest | 0 | 0 | -300K | -611K | -818K | 0 | 0 | 0 |
| EPS (Diluted) | -18.50▲ 0% | -4.00▲ 78.4% | -27.25▼ 581.3% | -6.50▲ 76.1% | -16.00▼ 146.2% | -15.75▲ 1.6% | -24.50▼ 55.6% | -22.42▲ 0% |
| EPS Growth % | - | 78.38% | -581.25% | 76.15% | -146.15% | 1.56% | -55.56% | -53.9% |
| EPS (Basic) | -18.50 | -4.00 | -27.25 | -6.50 | -16.00 | -15.75 | -24.50 | - |
| Diluted Shares Outstanding | 15.36M | 15.39M | 14.92M | 16.33M | 16.36M | 16.44M | 16.56M | 16.66M |
| Basic Shares Outstanding | 15.36M | 15.39M | 14.92M | 16.33M | 16.36M | 16.44M | 16.56M | 16.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
AGL Balance Sheet
Agilon Health, Inc. (AGL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 245.53M | 294.2M | 1.37B | 1.45B | 1.48B | 1.46B | 1.1B | 1.32B |
| Cash & Short-Term Investments | 123.63M | 106.8M | 1.05B | 877.2M | 495.1M | 405.6M | 285.14M | 231.41M |
| Cash Only | 123.63M | 106.8M | 1.05B | 465.3M | 114.33M | 193.86M | 173.71M | 139.99M |
| Short-Term Investments | 0 | 0 | 0 | 411.9M | 380.77M | 211.74M | 111.43M | 91.42M |
| Accounts Receivable | 93.25M | 144.56M | 293.41M | 492.36M | 942.46M | 1.02B | 673.79M | 899.75M |
| Days Sales Outstanding | 42.85 | 43.31 | 70.39 | 75.25 | 79.7 | 61.25 | 41.45 | 55.94 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 24.33M | 33.21M | 18.97M | 81.71M | 42.51M | 35.14M | 137.76M | 190.02M |
| Total Non-Current Assets | 157.27M | 152.16M | 219.06M | 246.19M | 260.79M | 276.21M | 174.59M | 183.76M |
| Property, Plant & Equipment | 18.84M | 16.04M | 20.9M | 31.95M | 40.99M | 36.95M | 25.42M | 24.89M |
| Fixed Asset Turnover | 42.18x | 75.95x | 72.80x | 74.74x | 105.31x | 164.01x | 233.41x | 199.62x |
| Goodwill | 41.54M | 41.54M | 0 | 2.51M | 24.13M | 24.13M | 0 | 0 |
| Intangible Assets | 71.15M | 60.47M | 96.94M | 18.45M | 63.77M | 72.77M | 65.72M | 62.45M |
| Long-Term Investments | 0 | 8.5M | 6.69M | 17.35M | 44.75M | 61.76M | 59.79M | 228.16M |
| Other Non-Current Assets | 25.74M | 25.61M | 94.53M | 175.93M | 87.15M | 80.6M | 23.66M | 214.73M |
| Total Assets | 402.79M▲ 0% | 446.36M▲ 10.8% | 1.59B▲ 255.4% | 1.7B▲ 7.0% | 1.74B▲ 2.6% | 1.73B▼ 0.4% | 1.27B▼ 26.7% | 1.5B▲ 0% |
| Asset Turnover | 1.97x | 2.73x | 0.96x | 1.41x | 2.48x | 3.50x | 4.67x | 3.83x |
| Asset Growth % | - | 10.82% | 255.37% | 7.01% | 2.56% | -0.4% | -26.68% | -93.32% |
| Total Current Liabilities | 199.61M | 266.83M | 356.96M | 535.09M | 977.16M | 1.15B | 1.08B | 1.27B |
| Accounts Payable | 188.26M | 260.11M | 348.65M | 478.23M | 968.06M | 1.15B | 1.06B | 0 |
| Days Payables Outstanding | 89.72 | 84.45 | 87.42 | 76.66 | 83.2 | 69.29 | 63.04 | 47.69 |
| Short-Term Debt | 3.04M | 3.04M | 8.31M | 5M | 9.1M | 2.46M | 19.24M | 14.75M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 8.31M | 3.68M | 0 | 51.87M | 0 | 0 | 0 | 1.26B |
| Current Ratio | 1.23x | 1.10x | 3.83x | 2.71x | 1.51x | 1.27x | 1.02x | 1.02x |
| Quick Ratio | 1.23x | 1.10x | 3.83x | 2.71x | 1.51x | 1.27x | 1.02x | 1.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 8.25 |
| Total Non-Current Liabilities | 435.21M | 464.26M | 137.7M | 121.77M | 102.69M | 111.02M | 68.07M | 51.18M |
| Long-Term Debt | 67.14M | 64.67M | 43.4M | 38.48M | 32.31M | 34.9M | 15.75M | 15.28M |
| Capital Lease Obligations | 7.74M | 5.51M | 7.9M | 9.09M | 10.9M | 6.6M | 1.83M | 10.41M |
| Deferred Tax Liabilities | 12.82M | 10.01M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 347.51M | 384.07M | 86.39M | 74.19M | 59.48M | 69.52M | 50.49M | 182.98M |
| Total Liabilities | 634.82M | 731.09M | 494.66M | 656.86M | 1.08B | 1.26B | 1.14B | 1.32B |
| Total Debt | 77.92M | 73.21M | 59.61M | 52.57M | 52.31M | 43.96M | 36.81M | 30.02M |
| Net Debt | -45.71M | -33.58M | -995.21M | -412.73M | -62.02M | -149.9M | -136.9M | -109.96M |
| Debt / Equity | - | - | 0.05x | 0.05x | 0.08x | 0.09x | 0.29x | 0.29x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.30x |
| Interest Coverage | -11.65x | -6.66x | -61.31x | -19.22x | -28.21x | -39.28x | -59.85x | -119.84x |
| Total Equity | -232.03M▲ 0% | -284.73M▼ 22.7% | 1.09B▲ 483.4% | 1.04B▼ 4.7% | 661.02M▼ 36.5% | 470.95M▼ 28.8% | 126.73M▼ 73.1% | 181.43M▲ 0% |
| Equity Growth % | - | -22.71% | 483.38% | -4.67% | -36.48% | -28.75% | -73.09% | -223.07% |
| Book Value per Share | -15.11 | -18.50 | 73.18 | 63.74 | 40.41 | 28.65 | 7.65 | 10.89 |
| Total Shareholders' Equity | -232.03M | -284.73M | 1.09B | 1.04B | 661.84M | 470.95M | 126.73M | 181.43M |
| Common Stock | 2.47M | 2.49M | 4M | 4.12M | 4.06M | 4.12M | 4.15M | 166K |
| Retained Earnings | -491.14M | -551.19M | -957.68M | -1.06B | -1.33B | -1.59B | -1.98B | -1.93B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -5.56M | -2.3M | -88K | 916K | 479K |
| Minority Interest | 0 | 0 | -300K | -611K | -818K | 0 | 0 | 0 |
AGL Cash Flow Statement
Agilon Health, Inc. (AGL) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -103.86M | -53.2M | -148.16M | -130.81M | -156.2M | -57.78M | -105.76M | -105.76M |
| Operating CF Margin % | -13.07% | -4.37% | -9.74% | -5.48% | -3.62% | -0.95% | -1.78% | - |
| Operating CF Growth % | - | 48.77% | -178.47% | 11.71% | -19.41% | 63.01% | -83.05% | -274.02% |
| Net Income | -282.74M | -60.05M | -406.79M | -106.86M | -262.8M | -260.1M | -391.35M | -373.49M |
| Depreciation & Amortization | 41.41M | 14.1M | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M | 28.5M |
| Stock-Based Compensation | 5.22M | 6.69M | 292.39M | 28.38M | 69.33M | 50.66M | 49.12M | 38.65M |
| Deferred Taxes | -16.18M | -2.81M | -3.23M | 532K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 115.24M | -17.6M | 9.82M | -7.19M | 27.18M | -3.38M | 18.4M | 9.07M |
| Working Capital Changes | 33.18M | 6.47M | -55.02M | -59.44M | -10.07M | 130.59M | 189.47M | 228.26M |
| Change in Receivables | -23.28M | -59.38M | -149.04M | -204.17M | 0 | -74.58M | 344.58M | 0 |
| Change in Inventory | 0 | 0 | 149.04M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 38.26M | 67.31M | 95.7M | 173.45M | 473.61M | 198.58M | -87.48M | 0 |
| Cash from Investing | -5.06M | 22.07M | -90.51M | -444.39M | -44.02M | 139.89M | 88.61M | 130.97M |
| Capital Expenditures | -3.91M | -2.35M | -13.43M | -15.43M | -15.83M | -13.25M | -13.24M | -31.22M |
| CapEx % of Revenue | 0.49% | 0.19% | 0.88% | 0.65% | 0.37% | 0.22% | 0.22% | - |
| Acquisitions | 0 | 26.2M | -1.34M | 500K | -43.06M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -1.15M | -1.79M | -75.74M | -23.75M | -34.51M | -41.77M | -31.87M | -6.13M |
| Cash from Financing | 176.3M | 24.62M | 1.15B | 28.06M | -193.13M | -2.58M | -2.99M | -7.98M |
| Debt Issued (Net) | -3.59M | -3.04M | -19.9M | -5M | -5M | -3.75M | 0 | 0 |
| Equity Issued (Net) | 180.19M | 27.66M | 1.19B | 33.06M | -200M | 1.17M | -2.99M | -2.83M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -6.74M | 0 | 0 | -200M | 0 | -2.99M | -2.83M |
| Other Financing | -303K | 0 | -14.74M | 0 | 11.87M | 0 | 0 | -5.15M |
| Net Change in Cash | 67.38M▲ 0% | -6.52M▼ 109.7% | 915.73M▲ 14151.3% | -547.14M▼ 159.7% | -393.35M▲ 28.1% | 79.53M▲ 120.2% | -20.15M▼ 125.3% | 72.94M▲ 0% |
| Free Cash Flow | -107.77M▲ 0% | -55.55M▲ 48.4% | -161.59M▼ 190.9% | -163.47M▼ 1.2% | -187.01M▼ 14.4% | -71.03M▲ 62.0% | -119M▼ 67.5% | -76.61M▲ 0% |
| FCF Margin % | -13.57% | -4.56% | -10.62% | -6.84% | -4.33% | -1.17% | -2.01% | -1.32% |
| FCF Growth % | - | 48.45% | -190.86% | -1.17% | -14.4% | 62.02% | -67.55% | -26.21% |
| FCF per Share | -7.02 | -3.61 | -10.83 | -10.01 | -11.43 | -4.32 | -7.19 | -7.19 |
| FCF Conversion (FCF/Net Income) | 0.37x | 0.89x | 0.36x | 1.23x | 0.59x | 0.22x | 0.26x | 0.21x |
| Interest Paid | 0 | 7.09M | 4.82M | 3.67M | 5.8M | 4.6M | 0 | 1.31M |
| Taxes Paid | 0 | 2K | 1.82M | 5.31M | 5.36M | 1.8M | 0 | 146K |
AGL Key Ratios
Agilon Health, Inc. (AGL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -100.76% | -9.99% | -30.86% | -45.96% | -135.64% | -146.01% |
| Return on Invested Capital (ROIC) | - | -289.64% | -21.82% | -28.38% | -47.63% | -203.16% | -203.16% |
| Gross Margin | 7.73% | 4.32% | 4.66% | 1.61% | 0.08% | -3.18% | -3.87% |
| Net Margin | -4.93% | -26.72% | -4.46% | -6.08% | -4.29% | -6.83% | -6.42% |
| Debt / Equity | - | 0.05x | 0.05x | 0.08x | 0.09x | 0.29x | 0.29x |
| Interest Coverage | -6.66x | -61.31x | -19.22x | -28.21x | -39.28x | -59.85x | -119.84x |
| FCF Conversion | 0.89x | 0.36x | 1.23x | 0.59x | 0.22x | 0.26x | 0.21x |
| Revenue Growth | 53.36% | 24.88% | 56.97% | 80.74% | 40.41% | -2.11% | -2.82% |
AGL SEC Filings & Documents
Agilon Health, Inc. (AGL) SEC filings — annual & quarterly reports (10-K, 10-Q)
AGL Frequently Asked Questions
Agilon Health, Inc. (AGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Agilon Health, Inc. (AGL) reported $5.82B in revenue for fiscal year 2025. This represents a 633% increase from $794.4M in 2019.
Agilon Health, Inc. (AGL) saw revenue decline by 2.1% over the past year.
Agilon Health, Inc. (AGL) reported a net loss of $373.5M for fiscal year 2025.
Dividend & Returns
Agilon Health, Inc. (AGL) has a return on equity (ROE) of -135.6%. Negative ROE indicates the company is unprofitable.
Agilon Health, Inc. (AGL) had negative free cash flow of $76.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More AGL
Agilon Health, Inc. (AGL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates